NUVBHealthcare · BiotechnologyThe 9 Wall Street analysts covering Nuvation Bio, Inc. hold a median 12-month price target of $12 — +84.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Nuvation Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NUVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +84.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $19 → $20 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Buy | $17 → $21 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 July 2026 | Wedbush | Reiterates | Outperform | $11 |
| 23 July 2026 | Wedbush | Reiterates | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $20 → $19 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $12 → $13 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 5 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | RBC Capital | Reiterates | Outperform | — |
| 5 May 2026 | Wedbush | Reiterates | Outperform | — |
| 16 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 2 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 27 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 3 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 3 Mar 2026 | UBS | Maintains | Neutral | — |
| 10 Feb 2026 | Wedbush | Reiterates | Outperform | — |
| 21 Jan 2026 | RBC Capital | Maintains | Outperform | — |
| 12 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUVB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 12% of US stocks
Cheaper than 13% of US stocks
Cheaper than 87% of US stocks
Higher than 98% of US stocks
Higher than 96% of US stocks
Higher than 83% of US stocks
Higher than 11% of US stocks
Higher than 6% of US stocks
Higher than 22% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuvation Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nuvation Bio reported Q2 total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, and noted that use of the ROS1-targeted lung cancer therapy continued shifting toward first-line patients.
Why it matters — The revenue update and shift to first-line use of IBTROZI provide an early look at the commercial trajectory of Nuvation Bio's key approved product.
Seeking Alpha published the transcript of Nuvation Bio Inc.'s Q2 2026 earnings call, covering the company's quarterly conference call with investors and analysts.
Why it matters — A NUVB watcher would care because the transcript provides direct insight into management's own discussion of the company's quarter.
Nuvation Bio reported a Q2 loss of $0.15 per share, in line with the Zacks Consensus Estimate and improved from a $0.17 per share loss a year earlier.
Why it matters — A Nuvation Bio watcher would care because the quarter matched analyst expectations while narrowing the year-over-year loss.
Nuvation Bio reported second quarter 2026 financial results, with $31.7 million in total revenue including $23.2 million in net product revenue for IBTROZI, and announced positive updated Phase 2 data for safusidenib plus an expanded clinical program for IDH1-mutant glioma. The company also reported $661.0 million in cash and marketable securities as of June 30, 2026, with an additional $36.5 million in net proceeds from the convertible notes overallotment option.
Why it matters — NUVB watchers would care because IBTROZI has become the most prescribed ROS1 TKI in new patient starts and the company is advancing a broader IDH1-mutant glioma program while maintaining a robust cash position.
Nuvation Bio announced that new subgroup analyses of long-term Phase 2 data from the pivotal TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) in advanced ROS1-positive non-small cell lung cancer will be presented at the WCLC in Seoul (September 12-15, 2026) and the ESMO Congress in Madrid (October 23-27, 2026). The analyses will examine the consistency of efficacy and safety of IBTROZI across key patient subgroups.
Why it matters — A NUVB watcher would care because these presentations share additional long-term pivotal data on IBTROZI's efficacy and safety across key patient subgroups, offering further insight into the drug's profile ahead of the 2026 medical congresses.
The 9 Wall Street analysts covering Nuvation Bio, Inc. have a median 12-month price target of $12, with estimates ranging from $7 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Nuvation Bio, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvation Bio, Inc. 62 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Nuvation Bio, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +84.9% from the last close, and Ticker Nerd's factor model ranks Nuvation Bio, Inc. 62 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nuvation Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUVB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $20 over the next 12 months.
Nuvation Bio, Inc. returned +125.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Nuvation Bio Inc. is a commercial-stage biopharmaceutical company specializing in oncology therapies.
The most recent item we track (MarketBeat, 8 Aug 2026): "Nuvation Bio Q2 Earnings Call Highlights". Nuvation Bio reported Q2 total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, and noted that use of the ROS1-targeted lung cancer therapy continued shifting toward first-line patients.
Nuvation Bio Inc. is a commercial-stage biopharmaceutical company specializing in oncology therapies. The company focuses on cancers with clear molecular drivers and high unmet medical need, emphasizing precision oncology for difficult-to-treat solid tumors. Its current portfolio centers on targeted small-molecule drugs, including taletrectinib, a next-generation ROS1 inhibitor marketed for ROS1-positive non-small cell lung cancer, and safusidenib, a brain-penetrant inhibitor of mutant IDH1 designed for IDH1-driven tumors. Nuvation Bio also advances an innovative drug-drug conjugate program, using proprietary small-molecule constructs to deliver dual therapeutic modalities in a single agent. Operating today as a development-and-commercialization coordinator rather than a large-scale manufacturer, the company creates value by selecting, developing, regulating, and commercializing specialized oncology medicines. Founded in 2018 and headquartered in New York, with additional offices in San Francisco, Boston, and Shanghai, Nuvation Bio plays a growing role in the global market for targeted cancer therapies.
CEO Dr. David T. Hung M.D. · 305 employees · United States · https://www.nuvationbio.com